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OBJECTIVE: To evaluate the knowledge and acceptability of the human papillomavirus (HPV) vaccine among
health professionals from western Amazonia.
METHODS: A cross-sectional study was conducted in the Sistema Assistencial a` Sau´de da Mulher e da Crianc¸a
(Health Care System for Women and Children; SASMC) in Acre, Brazil, in 2017. The participants comprised
196 health professionals. The data collection instrument contained 31 questions about HPV, its clinical
repercussions for women, and the HPV vaccine. Quantitative variables were presented as medians and 95%
confidence intervals (CIs), and po0.05 was considered statistically significant. For the analyses, chi-square tests
and Mann-Whitney tests were used. The collected data were analyzed using Statas11.0.
RESULTS: Of the 196 health professionals, 39.8% (n=76) were physicians and 61.2% (n=120) were other health
professionals. The interviewees were mostly female (n=143, 73%, 95% CI 66.1 to 78.9%) who worked in the
medical field (n=81, 41.3%, 95% CI 34.4 to 48.6%), and the median age was 38 years (95% CI 36.0 to 39.7).
Physicians had increased knowledge regarding only the statement "cervical cancer is one of the main causes of
cancer in women", with a proportion ratio of 0.88 (0.80; 0.97) and po0.001. Regarding clinical knowledge of
the HPV vaccine, a low proportion of correct answers was obtained for all the questions, and no significant
differences were found between the groups.
CONCLUSION: Acceptability and knowledge of HPV and its vaccine were similar among health professionals,
with knowledge gaps in questions about the relation between smoking and cervical cancer and specific clinical
knowledge.
KEYWORDS: HPV; Papillomavirus Vaccines; Knowledge; Health Professional.
’ INTRODUCTION
Human papillomavirus (HPV) infections of the genital
tract (1) are related to cervical cancer. Thus, HPV is the third
most prevalent cause of tumors and the fourth leading cause
of death due to cancer in Brazil (2). The persistence of
oncogenic HPV subtypes, especially 16 and 18, is related to
more than 80% of cervical cancer cases (3) as well as other
cancers. Conversely, subtypes 6 and 11 are nononcogenic and
are associated with genital warts (4).
The primary prevention strategies for HPV infection are
vaccination and condom use. The quadrivalent vaccine
(Gardasil TM) is composed of noninfectious antigenic partic-
les capable of inducing a protective immune response (5,6),
and the target populations for the quadrivalent HPV vaccine are
girls 9 to 14 years of age and boys 11 to 14 years of age (7). Both
are available from the Brazilian health care system at no cost.
The World Health Organization (WHO) considers vaccina-
tion coverage adequate when inoculations of the second dose
reach 80% in the target populations (1). In Brazil and the
Federative Unit of Acre, 100% adherence was achieved for
the first vaccine dose, and 64.48% and 49.84% adherence
rates were achieved for the second doses in girls and boys in
2017, respectively (8).
Acceptability of the vaccine contributes to adherence in
vaccination campaigns and is influenced by social, economic,DOI: 10.6061/clinics/2019/e1166
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and cultural factors as well as the population’s confidence in
its safety and efficacy (9). Health professionals affect the
decision-making of patients and guardians regarding vacci-
nation (10-12) by minimizing vaccination barriers and
increasing the acceptability of the prevention method through
cultural guidance and demystification (13).
Territorial studies can contribute to improving public
health by helping identify gaps in knowledge among health
professionals and thus promoting territorial health educa-
tion. The objective of this study was to evaluate the know-
ledge and acceptability of the HPV vaccine among health
professionals in the western Amazon.
’ METHODS
Study Design
This cross-sectional study was conducted in the Sistema
Assistencial à Saúde da Mulher e da Crianc¸a (Health Care
System for Women and Children; SASMC) in the state of
Acre, Brazil, from January to March 2017.
Acre state is a Brazilian Federative Unit localized in northern
Brazil and has a territorial extension of 164.221,36 km2
(2% of Brazilian territory, approximately); Acre had a Human
Development Index of 0.66 (Brazil was 0.72) and a Gini index
of 0.63 (Brazil was 0.60) in 2010. One hundred percent
adherence was achieved for the first vaccine dose and 78.48%
and 42.1% adherence rates were achieved for the second
doses in girls and boys in 2017, respectively (8).
Population
Physicians and health professionals of both sexes who
were over 18 years of age and participated in the study were
enrolled through convenience sampling. All participants
signed the Free and Informed Consent Form, and the study
was approved by the Research Ethics Committee of the
Faculdade de Medicina da Universidade de São Paulo
(School of Medicine of the University of São Paulo) - USP
(205/14) and the União Educacional do Norte (North
Education Union) - UNINORTE (2.158.359).
A pilot study with 20 individuals was performed to
identify the parameters required to calculate the sample size.
The statistical parameters used were as follows: the means
(standard deviations (sds)) of the overall score between
physicians (85.4; sd=5.4) and other health professionals
(80; sd=17.6), a test power of 80%, and a standard error of
5% for a bilateral test. A sample loss of 20% (n=32) was
considered, resulting in an estimated size of 192 individuals.
Data Collection Procedure
The collection instrument for the evaluation of knowledge
and acceptability of the HPV vaccine among health profes-
sionals contained a sociodemographic evaluation (sex, mari-
tal status, number of children, profession, family income,
schooling, and type of higher education). The instrument
was composed of 31 questions, including 24 questions cover-
ing HPV knowledge topics, HPV vaccine knowledge, HPV
vaccination barriers, and HPV vaccine acceptability; 3 (three)
questions on personal history related to cervical cancer and
genital warts in female subjects; and 4 (four) questions about
the HPV vaccine in special situations (pregnancy and immu-
nocompromised patients) (14).
The response options for the instrument questions
were yes, no, and not sure. The questions were grouped by
theme to score the answers, with one point assigned to each
question answered correctly. The scores were inverted for
questions 11, 12, 19, and 31.
The overall score weighting was calculated from the
24 questions covering knowledge topics about HPV, the
vaccine, barriers to vaccination, and acceptability of the HPV
vaccine. Questions 1, 15, 22, 23, 25, 26, and 27 were
considered personal responses and were not counted in the
overall score.
A good level of knowledge and acceptability was con-
sidered when the mean overall score was equivalent to
80% correct answers; the score was calculated as the sum of
correct answers divided by the total number of questions, as
shown in the formula below:
P
correct answers
24 questions related to knowledge
 100
Data Analysis
The data collected were tabulated using a Microsoft Excel
spreadsheet. Qualitative variables were presented as abso-
lute and relative frequencies with their respective 95%
confidence intervals (CIs). Quantitative variables were pre-
sented as medians and 95% CIs because they did not have
normal distributions (evaluated by the Shapiro-Wilk test,
po0.05). To analyze the differences in characteristics between
physicians and other health professionals, the chi-square test
was used for qualitative variables, and the Mann-Whitney test
was used for quantitative variables.
Poisson regression with robust variance adjusted for sex,
stable union, age, and income was used to estimate the
proportion of correct answers to questions related to HPV
knowledge between the groups. Interquartile regression
adjusted for sex, stable union, age, and income was used to
analyze the median difference in the overall HPV knowl-
edge scores between groups. The confidence level used was
5%, and the software used for the analysis was Statas
(StataCorp. 2009. Stata Statistical Software: Release 11. College
Station, TX: StataCorp LP).
’ RESULTS
A total of 196 health professionals, consisting of 39.8%
(n=76) physicians and 61.2% (n=120) other health profes-
sionals, were divided into two groups and interviewed. The
professionals were predominantly female (n=143, 73%, 95%
CI 66.1 to 78.9%) with a stable union (n=109, 58.6%, 95% CI
51.1 to 65.7%) and children (n=130, 67.4%, 95% CI 60.2 to
73.8%), and nearly half were physicians (n=81, 41.3%, 95% CI
34.4 to 48.6%). Overall, the median age of the sample was
38 years (95% CI 36.0 to 39.7), and the respondents had a
median of 2 children.
The ages and number of children did not differ between
the groups (assessed by the interval estimate and 95% CI
of the proportions). The proportion of individuals with
an income above 10 wages was significantly higher in the
group of physicians than in the group of other professional
(po0.001) (Table 1).
A knowledge gap with a proportion of 71.9% (95% CI 65.0;
78.0) was identified among all health professionals in response
to the question "Smoking may increase the risk of cervical
cancer", with no difference observed between the groups
(Table 2).
According to the parameters used in the study, a low
proportion of correct answers regarding the HPV vaccine
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was found for the following questions: "Can the HPV vaccine
be given to those who have had sexual intercourse?" (74.0%,
95% CI 67.1; 79.9); "Can the HPV vaccine be harmful to
health?" (77.6%, 95% CI 70.9; 83.1); "Can the HPV vaccine
cause infection?" (75.0%, 95% CI 68.2; 80.8); "Is the HPV
vaccine part of the girls’ immunization records?" (73%, 95%
CI 66.1; 78.9); "Is it necessary to take 3 doses for complete
vaccination?" (61.2%, 95% CI 54.0; 68.0); and "Does the HPV
vaccine decrease the odds of contracting genital warts?"
(71.9%, 95% CI 65.0; 78.0) (Table 2).
In the analysis between physicians and other health
professionals, increased knowledge of the physicians was
observed regarding only the statement "Cervical cancer is
one of the main causes of cancer in women", with a propor-
tion ratio of 0.88 (0.80; 0.97) and po0.001 (Table 2).
The perceptions regarding barriers to vaccination and
acceptability were not different between the physicians and
other health professionals, as observed by the CIs of the
interval estimates of the proportion ratios and their
respective p values. The personal backgrounds of the
female professionals presented a relatively low propor-
tion of nonmedical professionals; 29% (PR: 0.71; 95% CI
0.29 to 1.74) had little knowledge about abnormal Pap
smear results and 83% (PR: 0.17; 95% CI 0.03 to 1.12)
demonstrated little knowledge about a genital warts report
(Table 3).
Regarding clinical knowledge of the HPV vaccine, a low
proportion of correct answers was found for all questions, and
no significant differences were found between the groups
(Table 4).
Table 1 - Socioeconomic characteristics of the physicians and other health professionals interviewed in the Health Care System for
Women and Children (SASMC) in the state of Acre, Brazil, in 2017.
Characteristics Physicians Other health professionals p-value*
(n=76; 39.8%) (n=120; 61.2%)
n % (95% CI) n % (95% CI)
Sex
Male 28 20.2 (12.9; 27.5) 24 36.8 (25.9; 47.8) 0.01
Female 48 79.8 (72.5; 87.1) 95 63.2 (52.1; 74.1)
Stable union
No 23 47.4 (38.1; 56.6) 54 31.9 (21.0; 42.9) 0.04
Yes 49 52.6 (43.3; 61.9) 60 68.1 (57.1; 79.0)
Children
No 18 38.1 (29.3; 47.0) 45 24.0 (14.2; 33.8) 0.04
Yes 57 61.9 (53.0; 70.7) 73 76.0 (66.2; 85.8)
Income
Up to 10 times the normal wage 11 20.9 (13.2; 28.6) 87 84.7 (76.3; 93.1) o0.001
Above 10 times the normal wage 61 79.1 (71.4; 86.8) 23 15.3 (6.9; 23.7)
Median (95% CI) Median (95% CI) p-value**
Age 40 (38; 43) 36 (34; 39) 0.006
Number of children 2 (1;2) 2 (2;2) 0.15
*Chi-square;
**Mann-Whitney (as assessed by interval estimation and 95% confidence intervals of proportions).
Table 2 - Knowledge of HPV among physicians and other health professionals interviewed in the Health Care System for Women and
Children (SASMC) in the state of Acre, Brazil, in 2017.
Knowledge of HPV
and HPV vaccine
Total Physicians Other health
professionals
RP p-
value*
% (95% CI) N % N
Do you know what HPV is? 96.9 (93.1; 98.7) 190 98.7 (75) 95.8 (115) 0.93 (0.85; 1.01) 0.11
Is HPV a virus? 98.0 (94.5; 99.3) 192 98.7 (75) 97.5 (117) 0.95 (0.90; 1.00) 0.08
Is HPV a sexually transmitted disease? 98.0 (94.5; 99.3) 192 98.7 (75) 97.5 (117) 0.97 (0.93; 1.01) 0.15
Can HPV cause cervical cancer? 98.0 (94.5; 99.3) 192 100.0 (76) 96.7 (116) 0.96 (0.92; 1.01) 0.14
Can HPV cause changes in the Pap smear test? 93.4 (88.7; 96.3) 183 97.4 (74) 90.8 (109) 0.94 (0.84; 1.04) 0.24
Is cervical cancer a major cancer in women? 91.3 (86.3; 94.7) 179 97.4 (74) 87.5 (105) 0.88 (0.80; 0.97) 0.01
Can smoking increase the risk of cervical cancer? 71.9 (65.0; 78.0) 141 79.0 (60) 67.5 (81) 0.98 (0.79; 1.20) 0.83
Does the HPV vaccine prevent cervical cancer? 87.2 (81.6; 91.4) 171 90.8 (69) 85.0 (102) 0.91 (0.78; 1.05) 0.21
Should the HPV vaccine be given before the first sexual intercourse? 93.9 (89.3; 96.7) 184 93.4 (71) 94.2 (113) 1.00 (0.93; 1.2) 0.46
Can the HPV vaccine be given to people who have had sex? 74.0 (67.1; 79.9) 145 75.0 (57) 73.3 (88) 1.01 (0.82; 1.26) 0.86
Can the HPV vaccine be harmful to your health? 77.6 (70.9; 83.1) 152 75.0 (57) 79.2 (95) 1.15 (0.93; 1.41) 0.19
Can the HPV vaccine cause HPV infection? 75.0 (68.2; 80.8) 147 84.2 (64) 69.2 (83) 0.93 (0.76; 1.12) 0.43
Is the HPV vaccine provided by the government? 94.4 (89.9; 97.0) 185 92.1 (70) 95.8 (115) 0.98 (0.91; 1.05) 0.61
Is the HPV vaccine part of the girls’ immunization records? 73.0 (66.1; 78.9) 143 71.1 (54) 74.2 (89) 0.91 (0.74; 1.12) 0.40
Are 3 doses required for complete vaccination? 61.2 (54.0; 68.0) 120 61.8 (47) 60.8 (73) 0.82 (0.61; 1.11) 0.20
Does the HPV vaccine decrease the chance of having genital warts? 71.9 (65.0; 78.0) 141 81.6 (62) 65.8 (79) 0.85 (0.65; 1.10) 0.22
Does the HPV vaccine decrease the chance of having changes in the
Pap smear test?
80.6 (74.2; 85.8) 158 85.5 (65) 77.5 (93) 0.87 (0.71; 1.07) 0.21
RP: Ratio of proportions;
* Poisson regression adjusted for sex, stable union, age, and income was significant at po0.05.
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Among physicians, the proportion of correct answers
regarding general knowledge of HPV, its clinical repercussions,
and the HPV vaccine was 87.3% (range from 83.3 to 91.7%),
whereas among the other health professionals, this knowledge
was 83.3% (range from 79.2% to 84.4%). The difference was
not significant when adjusted for sex, stable union, age, and
income (Figure 1).
’ DISCUSSION
The analysis of health professionals in the western
Amazon who were interviewed about their knowledge of
the HPV virus, its repercussions for the health of women,
and its vaccine showed a knowledge gap concerning smok-
ing as a cofactor for the development of cervical cancer and a
low proportion of correct answers regarding HPV vaccine
safety, efficacy, and the vaccination schedule.
The interviewees were female, worked in the medical field,
and had stable unions and children. Cervical cancer affects
women who are in an economically active period of their life.
Since the interviews were conducted mainly with those in
the medical field, knowledge of the topic is justified.
The concept of health has been transformed on the basis of
historical experience, resulting in the appearance of new
formulations in public health and consequently new propo-
sals for changes in healthcare models. Vaccination for HPV
is an example of this change since its inclusion in the
vaccination program was necessary to solve the high rates of
uterine cervix cancer (15).
No barriers to vaccination were identified among the
respondents. However, the cost of the vaccine and
anticipation of the onset of sexual activity (16,17) are the
most cited items in the literature and are related to sexual
myths or prejudices regarding the vaccine. This finding
shows the need for clarification on the subject among
the interviewees who work in adolescent health in the
studied region.
The high number of correct answers regarding the need for
continued Pap smear procedures (secondary prevention for
cervical cancer) identified in this study suggested knowledge
of the importance of screening and early detection of cervical
cancer since the primary prevention offered by the quad-
rivalent HPV vaccine showed a reduction in the numbers of
low- and high-grade premalignant lesions identified by the
Pap smear test (18).
Table 3 - Barriers, acceptability, and personal antecedents related to the HPV vaccine among physicians and other health professionals
interviewed in the Health Care System for Women and Children (SASMC) in the state of Acre, Brazil, in 2017.
Domains Total Physicians Other health professionals RP p-
value*
% (95% CI) N % N
Barriers
Do you think the HPV vaccine will stimulate the
onset of sexual activity at an earlier age?
95.4 (91.2; 97.7) 187 96.1 (73) 95.0 (114) 0.99 (0.93; 1.06) 0.98
Do you think that you still need to use a condom
after HPV vaccination?
98.5 (95.2; 99.6) 193 100 (76) 97.5 (117) 0.94 (0.88; 1.01) 0.14
Do you think that you still need to have a Pap
smear test after HPV vaccination?
99.0 (96.0; 99.8) 194 100 (76) 98.3 (118) 0.95 (0.88; 1.02) 0.16
Acceptability
Do you know anyone who has already received the
HPV vaccine?
74.0 (67.1; 79.9) 145 75.0 (57) 73.3 (88) 0.89 (0.71; 1.10) 0.29
Have you received the HPV vaccine yet? 10.2 (6.5; 15.5) 20 10.5 (8) 10.0 (12) 0.80 (0.28; 2.27) 0.68
Would you recommend the HPV vaccine for a child,
friend, or relative?
93.4 (88.7; 96.3) 183 93.4 (71) 93.3 (112) 1.04 (0.96; 1.13) 0.34
Female personal history p**
Have you ever had an abnormal Pap smear? 20.3 (14.2; 28.0) 29 25.0 (12) 17.9 (17) 0.71 (0.29; 1.74) 0.46
Have you ever had cervical cancer? 2.1 (0.5; 6.5) 3 2.08 (1) 2.11 (2) 1.55 (0.24; 10.02) 0.64
Have you ever had genital warts? 5.6 (2.6; 11.1) 8 12.5 (6) 2.1 (2) 0.17 (0.03; 1.12) 0.07
RP: Ratio of proportions;
* Poisson regression adjusted by sex, stable union, and age
**Poisson regression adjusted for stable union and age
Table 4 - Clinical knowledge of the HPV vaccine among physicians and other health professionals interviewed in the Health Care
System for Women and Children (SASMC) in the state of Acre, Brazil, in 2017.
Domains Total Physicians Other health professionals RP p-value*
% (95% CI) N % N
Can patients living with HIV take the vaccine? 48.5 (41.3; 55.7) 95 56.6 (43) 43.3 (52) 0.76 (0.52; 1.11) 0.17
Do I feel confident indicating HPV vaccination
for patients?
79.1 (72.6; 84.4) 155 84.2 (64) 75.8 (91) 0.87 (0.73; 1.05) 0.15
Do I feel confident giving information about
HPV to patients?
67.2 (60.0; 73.6) 131 73.7 (56) 62.5 (75) 0.78 (0.60; 1.02) 0.08
Can pregnant women take the vaccine? 39.8 (33.0; 47.0) 78 39.5 (30) 40.0 (48) 0.88 (0.54; 1.44) 0.63
RP: Ratio of proportions;
* Poisson regression adjusted for sex, stable union, age, and income
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We emphasize the need for adequate knowledge of HPV,
its repercussions, and its relationship with cervical cancer
among health professionals. Smoking as a nonviral factor
associated with cervical cancer was considered a gap in
knowledge among the interviewees. Smoking is a risk factor
for the development of invasive cancer and cancer in situ
(19). Moreover, the risk of squamous cell carcinoma increases
with the number of cigarettes smoked per day and the onset
of smoking at an early age (19,20). Incentives for smoking
cessation in health promotion programs and healthy lifestyle
guidelines for the young population should be included in
health education by professionals.
HPV infection of the genital tract is considered the most
frequent viral infection among sexually active individuals
(21). The perception of HPV as a sexually transmitted infect-
ion among health professionals has been satisfactory. Studies
(22,23) conducted with similar groups have shown a lack of
knowledge about the sexual transmission of HPV according
to the professional’s area. Knowledge about the viral etio-
logy of HPV, its causal relationship with genital warts,
changes in Pap smear tests, and its association with cervical
cancer was similar among the professionals interviewed.
Health professionals have doubts about the vaccination
schedule advocated by the National Immunization Program.
Gaps in knowledge or doubts about the vaccination scheme
among health professionals have been shown to be similar in
developed and developing countries (12,23,24). Recommen-
dations for health professionals reinforce the validity of the
immunization program and increase vaccination coverage (22).
The National Immunization Program indicates vaccination
for HPV in men and women with HIV from 9 to 26 years of
age; this is a different population and a different age range
from those targeted in the campaign for HPV vaccination
among adolescents (7). These differences may contribute to
confusion among health professionals.
The existence of several HPV vaccines (bivalent, quad-
rivalent, and nonavalent) (25) as well as the adoption
of different vaccine schedules in countries that offer the
HPV vaccine free of charge may be confounding factors for
understanding the vaccination schedule among health
professionals.
The interviewees were not sure about the target or specific
population that should be vaccinated. Criteria for vaccina-
tion in women living with HIV as well as contraindications
in pregnant women should be emphasized in continuing
education as topics for health professionals.
The knowledge gap regarding vaccine indications in HIV-
positive individuals arises from misinformation about the
safety of the HPV vaccine in immunosuppressed patients.
The vaccine is safe in patients living with HIV and may be
given after a medical prescription because it contains no live
or attenuated virus but instead contains proteins without
viral particles (7,25-27).
A low level of correct answers about the nonuse of the
HPV vaccine in pregnant women was observed in the
present study. The HPV vaccine is not recommended for
pregnant women and is not part of the vaccine schedule
for this population. However, epidemiological surveillance
studies have indicated the nonteratogenicity of the vaccine
(28,29).
According to the Ministry of Health’s vaccine data, vaccine
coverage was 100% for the first dose in the state of Acre
(in western Amazonia); importantly, vaccine coverage above
80% is considered adequate (7). The interviewees showed
acceptance and willingness to recommend the HPV vaccine,
verifying the adequate vaccination coverage in the state of
Acre, which is positively related to acceptance of the HPV
vaccine among health professionals (11-13). Acceptance in
this group of professionals was similar in countries where
the vaccine was adopted in public health programs (30,31).
In a recent WHO review on the HPV vaccine, recommen-
dations were given to the scientific community regarding the
importance of encouraging the second dose and surveillance
in the target population because better outcomes are
obtained in reducing cervical cancer percussive lesions and
producing immune responses when the second dose is
completed (1). In Brazil, vaccination coverage for the second
dose of the HPV vaccine was 44.65% in 2015 and was 42.02%
Figure 1 - General knowledge of the HPV vaccine among physicians and other health professionals interviewed in the Health Care
System for Women and Children (SASMC) in the state of Acre, Brazil, in 2017. Interquartile regression*: b=-4.2 (95% CI -13.7 para 5.3);
p=0.10 *Adjusted by sex, stable union, age, and income.
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in the state of Acre, reinforcing the importance of health
education on this topic for professionals in this state (8).
Despite good acceptance, some professionals said they
were not vaccinated for HPV. The National Immunization
Program of the Ministry of Health does not include health
professionals as a target population, and the age group does
not correspond to the target population for vaccination (7).
The contribution of health professionals to adequate vaccination
coverage in our state can be broadened through the implemen-
tation of continuing education strategies for professionals and
can thus fill the knowledge gaps found in this study.
Knowledge regarding HPVamong the health professionals
in our study was similar among both medical graduates and
graduates from other health science courses. In contrast, with
our results, Nilse et al. (32) reported that nurses working in
public health had more knowledge about the topic than
physicians. Furthermore, a study conducted in the United
Kingdom and Ireland showed that health professionals in
general had good knowledge of HPV (33).
The acceptability of the HPV vaccine among health care
professionals in Acre was satisfactory based on our results,
with knowledge gaps among respondents regarding vaccine-
specific questions. Nurses, speech therapists, and other
health care professionals had more questions about specific
HPV vaccine factors than did oncologists (33).
Studies with a cross-sectional design are subject to reverse
causality (i.e., the impossibility of distinguishing the tempor-
ality between the levels of knowledge and the acceptability
of the HPV vaccine among health professionals). External
validity (the generalization of the results to other regions
of Brazil) is also a limitation because the population is a
convenience sample of health professionals in Acre.
Thus, the findings of this study showed knowledge gaps
regarding the nonviral cofactors related to cervical cancer
(smoking), the vaccination schedule, and the eligibility of
immunocompromised populations to receive the vaccine.
The topics of smoking and cervical cancer, the vaccina-
tion schedule for the quadrivalent HPV vaccine, and the
recommendations for vaccination of individuals living with
HIV should be included in continuing education for health
professionals.
’ CONCLUSIONS
Acceptability and knowledge of the HPV vaccine were
similar among medical and nonmedical health professionals.
Knowledge gaps were found regarding the vaccination
schedule, vaccine use among immunocompromised indivi-
duals and pregnant women, and the involvement of smoking
in the etiology of cervical cancer.
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